Viking Therapeutics prices USD 225 million convertible senior notes offering
Viking Therapeutics priced an upsized USD 225 million offering of 2.00% convertible senior notes due 2032. Settlement is scheduled for Sept. 25, subject to customary closing conditions. Underwriters hold a 30-day option to buy up to an additional USD 33.75 million principal amount to cover over-allotments. Notes conver